Acromegaly and Bone: An Update
Overview
Authors
Affiliations
Since our discovery in 2006 that acromegaly is associated with an increased risk of vertebral fractures, many authors have confirmed this finding in both cross-sectional and prospective studies. Due to the high epidemiological and clinical impact of this newly discovered comorbidity of acromegaly, this topic has progressively become more important and prominent over the years, and the pertinent literature has been enriched by new findings on the pathophysiology and treatment. The aim of this narrative review was to discuss these novel findings, integrating them with the seminal observations, in order to give the reader an updated view of how the field of acromegaly and bone is developing, from strong clinical observations to a mechanistic understanding and possible prevention and treatment.
Hong S, Han K, Park C Endocrinol Metab (Seoul). 2025; 40(1):1-9.
PMID: 39901807 PMC: 11898327. DOI: 10.3803/EnM.2024.2285.
Novel approach to bone comorbidity in resistant acromegaly.
Frara S, Acanfora M, Franzese V, Brandi M, Losa M, Giustina A Pituitary. 2024; 27(6):813-823.
PMID: 39570564 DOI: 10.1007/s11102-024-01468-y.
Modern approach to bone comorbidity in prolactinoma.
Uygur M, Menotti S, Santoro S, Giustina A Pituitary. 2024; 27(6):802-812.
PMID: 39541075 DOI: 10.1007/s11102-024-01469-x.
Pelsma I, Kroon H, Andela C, van der Linden E, Kloppenburg M, Biermasz N Pituitary. 2024; 27(6):824-836.
PMID: 39485592 PMC: 11632006. DOI: 10.1007/s11102-024-01465-1.
Growth hormone and bone: a basic perspective.
Bolamperti S, Villa I, Di Filippo L Pituitary. 2024; 27(6):745-751.
PMID: 39476263 DOI: 10.1007/s11102-024-01464-2.